Updates are available Correction dated 2022-03-23
Click to view Correction: https://doi.org/10.1038/s41571-022-00623-3
-
Authors
Weller, Michael
van den Bent, Martin https://orcid.org/0000-0001-5710-5127
Preusser, Matthias https://orcid.org/0000-0003-3541-2315
Le Rhun, Emilie
Tonn, Jörg C.
Minniti, Giuseppe https://orcid.org/0000-0003-1239-1603
Bendszus, Martin
Balana, Carmen https://orcid.org/0000-0003-0771-0390
Chinot, Olivier
Dirven, Linda
French, Pim https://orcid.org/0000-0002-0668-9529
Hegi, Monika E. https://orcid.org/0000-0003-0855-6495
Jakola, Asgeir S. https://orcid.org/0000-0002-2860-9331
Platten, Michael
Roth, Patrick
Rudà, Roberta
Short, Susan https://orcid.org/0000-0003-4423-7256
Smits, Marion https://orcid.org/0000-0001-5563-2871
Taphoorn, Martin J. B.
von Deimling, Andreas
Westphal, Manfred
Soffietti, Riccardo https://orcid.org/0000-0002-9204-7038
Reifenberger, Guido
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
- License Information
-
More Information
Article History
Accepted: 19 October 2020
First Online: 8 December 2020
Change Date: 23 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41571-022-00623-3
Competing interests
: M.W. reports grants and personal fees from Abbvie, Merck (EMD) and MSD, grants from Adastra, Dracen and Novocure, personal fees from Basilea, BMS, Celgene, Medac, Nerviano Medical Sciences, Orbus, Roche and Tocagen. M.vdB. reports personal fees from Abbvie, Agios, Bayer, Carthera, Genenta, Karyopharm and Nerviano Medical Sciences. M.Preusser reports grants and personal fees from Abbvie, Daiichi Sankyo, GlaxoSmithKline and MSD, grants from Böhringer Ingelheim, Bristol Myers Squibb, Novocure and Roche, and personal fees from AstraZeneca, Bayer, BMJ Journals, BMS, CMC Contrast, Gerson Lehrman Group, Lilly, Medahead, MedMedia, Mundipharma, Novartis, Roche, Sanofi and Tocagen. E.L.R. reports personal fees from Abbvie, Daiichy Sankyo and Tocagen. J.C.T. reports personal fees from BrainLab and Carthera. M.B. reports grants and personal fees from Novartis, grants from Siemens, and personal fees from B. Braun, Bayer, Boehringer Ingelheim, Grifols, Merck, Springer, Teva and Vascular Dynamics. C.B. reports personal fees from Celgene, Karyopharm, Lipopharma and Pharmamar, and other support from Abbvie. O.C. reports personal fees and travel support from Abbvie. M.E.H. reports funding from Bristol Myers Squibb and Novocure. A.S.J. reports personal fees from INOMED. M.Pl. reports non-financial support from Pfizer and Roche, personal fees and supply of reagents from Bayer, and personal fees from Affiris, Apogenix and Novartis. In addition, M.Pl has six patents licensed to Bayer (EP2753315B1, WO2018146010A1, WO2019101643A1, WO2019101647A1, WO2019101641A1 and WO2019101642A1), one patent issued (EP2800580B1) and three patents pending (US20180155403A1, US20180246118A1 and US20170254803A1). P.R. reports grants and personal fees from Novocure and personal fees from Bristol Myers Squibb, Debiopharm, Medac, Merck, MSD, QED and Roche. S.S. reports personal fees from Hox Therapeutics and Tocagen and personal fees and support of reagents from Abbvie. M.S. reports other support from GE Healthcare and Parexel. A.vD. receives royalties for the diagnostic use of IDH1 R132H mutant-specific antibody H09; all terms are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. R.S. reports personal fees from AstraZeneca, EISAI, Merck and Puma Biotechnologies. G.R. reports personal fees from Abbvie. G.M., L.D., P.F., R.R., M.J.B.T., M.W. and W.W. declare no competing interests.
